Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
about
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.Expanded strain coverage for a highly successful public health tool: prophylactic 9-valent human papillomavirus vaccine.Progress in HPV vaccination in low- and lower-middle-income countries.Adolescent human papillomavirus vaccination in the United States: Opportunities for integrating pharmacies into the immunization neighborhood.Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancer.The investment case for cervical cancer elimination.Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development.Use of a 2-Dose Schedule for Human Papillomavirus Vaccination-Updated Recommendations of the Advisory Committee on Immunization Practices.Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.9-Valent human papillomavirus vaccine: a review of the clinical development program.Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction.Primary Care Provider Practices and Perceptions Regarding HPV Vaccination and Anal Cancer Screening at a Boston Community Health Center.Major clinical research advances in gynecologic cancer in 2017.Vaccination programs for older adults in an era of demographic change.
P2860
Q38673370-5A7207A1-3ACE-4995-8A9A-A61B6F7EB310Q38682763-51DA0765-4845-4DAD-BE21-F992F04B7BC9Q39158741-E1B6BF64-A27A-4AE6-B4A1-EECC115C9D0EQ39366856-8F4558DF-3260-4DD8-8FC4-FE3458F1D566Q40168801-B8A9418B-6C2C-4EC0-A2B0-C205F465353DQ47136512-150147F8-E351-43E8-9AC0-2F7C71DAE01AQ47310121-94F293FA-1D1E-4B6C-8307-37E82A553C96Q47549756-5DD41BC4-D87E-4AF1-A581-2D171B5E11A6Q47874062-7AA001F6-E39A-473A-91F9-143B8E235EB1Q49206733-CCAC9F24-4D78-40E1-8D77-7A4A54C00AA9Q49687633-CB4A93A7-FF5E-44B8-845F-EF31E803F369Q54262416-9A03DF76-598E-4064-9843-DF1DDFA4FC63Q54266708-2A1E7CBA-8719-4DC9-A49E-4D0116342136Q54952356-DF08EF5D-408B-418B-BA80-09EB449A14C2Q54963907-EB8D2BFC-21FF-4B50-903F-A41DA3AA5B66
P2860
Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Immunogenicity of the 9-Valent ...... vs a 3-Dose Regimen in Women.
@en
type
label
Immunogenicity of the 9-Valent ...... vs a 3-Dose Regimen in Women.
@en
prefLabel
Immunogenicity of the 9-Valent ...... vs a 3-Dose Regimen in Women.
@en
P2093
P356
P1476
Immunogenicity of the 9-Valent ...... vs a 3-Dose Regimen in Women.
@en
P2093
Abdul Ghani Nur Azurah
Alain Luxembourg
Ales Skrivanek
Alfred J Saah
Angels Ulied
Erica Lazarus
Kulkanya Chokephaibulkit
Kyung-Hyo Kim
Maria Jose Miranda
Mark J DiNubile
P304
P356
10.1001/JAMA.2016.17615
P407
P577
2016-11-21T00:00:00Z